Engela Helena Conradie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Engela Helena Conradie has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Albe Carina Swanepoel
Centre for Human Metabolomics, North-West University, Potchefstroom, South Africa
3 shared publications A.D. Venter
1 shared publicationAbiola Oduwole
College of Medicine, University of Lagos/Lagos University Teaching Hospital, Lagos, Nigeria
1 shared publicationAndrew Auruku
Youth and Women for Opportunities Uganda, Eastern, Uganda
1 shared publicationAsmahan T. Abdalla
Department of Paediatrics, International University of Africa, Khartoum, Sudan
1 shared publication- Barend Christiaan Vorster
Centre for Human Metabolomics, North-West University, Potchefstroom, South Africa
1 shared publication
Latest Publications
- Open Access
- 5 February 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1) , 44
Improving access to rare disease diagnostics in Africa: insights from a multinational pilot study
Background: Rare diseases (RDs) in Africa face challenges such as limited diagnosis, expertise, and treatment. FYMCA Medical Ltd., the International Gaucher Alliance (IGA) and the Centre for Human Metabolomics (CHM) at North‒West University (NWU) launched a pilot study in 2022 to create an African RD diagnosis network, focusing on training clinicians and testing dried blood spot (DBS) samples for 6 lysosomal storage disorders (LSDs). The pilot study spanned eight sub-Saharan African countries (Nigeria, Ghana, Tanzania, Kenya, Mozambique, Uganda, Botswana, and Sudan), with samples sent to South Africa for analysis. Clinician training at the CHM was well received, with positive feedback suggesting hybrid learning for future sessions. Results: The project registered 56 samples in 27 months; Gaucher disease was most common. MPS II was the most prevalent MPS condition, with a prevalence resembling Eastern hemisphere patterns. Genetic variants were consistent with previous studies, but Fabry diagnoses were rare, which indicates the need for more focused programs. Conclusions: The high diagnostic yield for LSDs highlights the importance of targeted training and DBS cards for genetic testing. Challenges included sample integrity, referral gaps, and logistical delays. Addressing these barriers and fostering ongoing clinician engagement will enhance diagnostic capacity, whereas presenting findings at an African symposium will increase awareness.
- 5 February 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1) , 44
Open AccessImproving access to rare disease diagnostics in Africa: insights from a multinational pilot study
Background: Rare diseases (RDs) in Africa face challenges such as limited diagnosis, expertise, and treatment. FYMCA Medical Ltd., the International Gaucher Alliance (IGA) and the Centre for Human Metabolomics (CHM) at North‒West University (NWU) launched a pilot study in 2022 to create an African RD diagnosis network, focusing on training clinicians and testing dried blood spot (DBS) samples for 6 lysosomal storage disorders (LSDs). The pilot study spanned eight sub-Saharan African countries (Nigeria, Ghana, Tanzania, Kenya, Mozambique, Uganda, Botswana, and Sudan), with samples sent to South Africa for analysis. Clinician training at the CHM was well received, with positive feedback suggesting hybrid learning for future sessions. Results: The project registered 56 samples in 27 months; Gaucher disease was most common. MPS II was the most prevalent MPS condition, with a prevalence resembling Eastern hemisphere patterns. Genetic variants were consistent with previous studies, but Fabry diagnoses were rare, which indicates the need for more focused programs. Conclusions: The high diagnostic yield for LSDs highlights the importance of targeted training and DBS cards for genetic testing. Challenges included sample integrity, referral gaps, and logistical delays. Addressing these barriers and fostering ongoing clinician engagement will enhance diagnostic capacity, whereas presenting findings at an African symposium will increase awareness.
- 1 October 2025
- Published by SAGE Publications in Biopreservation and Biobanking
- Vol. 23 (5) , 414-420
Recruitment Strategies for a Nonhospital-Based Academic Rare Disease Biobank in South Africa
Introduction: Rare disease research in South Africa (SA) faces significant challenges, including limited prioritization and awareness, which hinder advancements in patient care and scientific discovery. This article explores the recruitment strategies employed by the Centre for Human Metabolomics (CHM) Biobank, a nonhospital-based academic rare disease biobank, to address these challenges. Methods: We explain the consent process and documents as well as the three recruitment models employed, namely (1) Recruitment via referring clinician, (2) implementation of monthly diagnostic follow-up sessions, and (3) recruitment of patients for specific projects through clinic-based recruitment drives. Discussion: We discuss the benefits as well as the challenges of each model. Challenges included clinician and patient time constraints, distrust from current consent practices, and limited public awareness. We elaborate on future strategies to address these gaps such as simplifying consent, expanding recruitment sites, collaborating with clinical, academic and public institutions, and raising public awareness of the role of the CHM Biobank. Conclusions: From the models employed over the past 5 years, it is evident that recruitment is most effective when patients perceive a direct benefit, such as involvement in active projects. These strategies outlined in the discussion are crucial for ensuring the CHM Biobank’s sustainability, diversity, and its impact on scientific research and patient outcomes in SA.
- 1 October 2025
- Published by SAGE Publications in Biopreservation and Biobanking
- Vol. 23 (5) , 414-420
Recruitment Strategies for a Nonhospital-Based Academic Rare Disease Biobank in South Africa
Introduction: Rare disease research in South Africa (SA) faces significant challenges, including limited prioritization and awareness, which hinder advancements in patient care and scientific discovery. This article explores the recruitment strategies employed by the Centre for Human Metabolomics (CHM) Biobank, a nonhospital-based academic rare disease biobank, to address these challenges. Methods: We explain the consent process and documents as well as the three recruitment models employed, namely (1) Recruitment via referring clinician, (2) implementation of monthly diagnostic follow-up sessions, and (3) recruitment of patients for specific projects through clinic-based recruitment drives. Discussion: We discuss the benefits as well as the challenges of each model. Challenges included clinician and patient time constraints, distrust from current consent practices, and limited public awareness. We elaborate on future strategies to address these gaps such as simplifying consent, expanding recruitment sites, collaborating with clinical, academic and public institutions, and raising public awareness of the role of the CHM Biobank. Conclusions: From the models employed over the past 5 years, it is evident that recruitment is most effective when patients perceive a direct benefit, such as involvement in active projects. These strategies outlined in the discussion are crucial for ensuring the CHM Biobank’s sustainability, diversity, and its impact on scientific research and patient outcomes in SA.
- 1 October 2025
- Published by SAGE Publications in Biopreservation and Biobanking
- Vol. 23 (5) , 396-403
Medical Biorepositories of South Africa: Establishing a Medical Biorepository Network in South Africa to Advance Health Research
Biobanking is crucial for advancing medical research and personalized medicine, offering high-quality biospecimens for studies on biomarkers, drug development, and diagnostics. Despite its global potential, challenges such as fragmented governance and varying standards hinder biorepository collaboration, particularly in South Africa (SA). A unified national biobank network could enhance research and healthcare by improving biospecimen access, ethical governance, and collaboration. Global biobank networks offer models for standardization, data sharing, and international cooperation. SA can benefit from these models by creating a centralized biobank platform, promoting capacity building, and fostering regional and global partnerships. To address the challenges SA faces regarding biobanking, the Medical Biobanks Cluster established a network named Medical Biorepositories of SA (MBirSA), which seeks to build a cohesive network of medical biorepositories in SA. Through this network, it plans to foster an inclusive culture of biospecimen and data protocol harmonization, while encouraging adherence to legal, ethical, and quality best practices and standards. The network aims to bring stakeholders together, increasing visibility and transparency, and encouraging sector-wide collaboration. MBirSA also aims to offer training to build capacity in global best practices, aid in the development of dependable biorepository infrastructure, and promote research partnerships to enhance healthcare advancements.
- 1 October 2025
- Published by SAGE Publications in Biopreservation and Biobanking
- Vol. 23 (5) , 396-403
Medical Biorepositories of South Africa: Establishing a Medical Biorepository Network in South Africa to Advance Health Research
Biobanking is crucial for advancing medical research and personalized medicine, offering high-quality biospecimens for studies on biomarkers, drug development, and diagnostics. Despite its global potential, challenges such as fragmented governance and varying standards hinder biorepository collaboration, particularly in South Africa (SA). A unified national biobank network could enhance research and healthcare by improving biospecimen access, ethical governance, and collaboration. Global biobank networks offer models for standardization, data sharing, and international cooperation. SA can benefit from these models by creating a centralized biobank platform, promoting capacity building, and fostering regional and global partnerships. To address the challenges SA faces regarding biobanking, the Medical Biobanks Cluster established a network named Medical Biorepositories of SA (MBirSA), which seeks to build a cohesive network of medical biorepositories in SA. Through this network, it plans to foster an inclusive culture of biospecimen and data protocol harmonization, while encouraging adherence to legal, ethical, and quality best practices and standards. The network aims to bring stakeholders together, increasing visibility and transparency, and encouraging sector-wide collaboration. MBirSA also aims to offer training to build capacity in global best practices, aid in the development of dependable biorepository infrastructure, and promote research partnerships to enhance healthcare advancements.
- Open Access
- 11 October 2023
- Published by The Royal Society in Royal Society Open Science
- Vol. 10 (10) , 230825
Feasibility of NAD(P)/NAD(P)H as redox agents in enzymatic plasmonic gold nanostar assays for galactose quantification
Plasmonic colorimetric sensors have emerged as powerful analytical tools in biochemistry due to their localized surface plasmon resonance extinction in the visible range. Here, we describe the feasibility of NAD(P)/NAD(P)H as redox agents in enzymatic plasmonic gold nanostar (AuNS) assays for galactose quantification using three model enzymes, GalDH, AR and GalOx, immobilized separately on polyvinylpyrrolidone-capped AuNS scaffolds. These highly specific, sensitive and selective bioassays induce the transformation of AuNS into quasi-spherical nanoparticles during the biorecognition of galactose in water and synthetic blood matrices. As a result, using our inexpensive and simple AuNS plasmon bioassays, the presence of galactose may be detected spectrophotometrically and by the naked eye.
- 11 October 2023
- Published by The Royal Society in Royal Society Open Science
- Vol. 10 (10) , 230825
Open AccessFeasibility of NAD(P)/NAD(P)H as redox agents in enzymatic plasmonic gold nanostar assays for galactose quantification
Plasmonic colorimetric sensors have emerged as powerful analytical tools in biochemistry due to their localized surface plasmon resonance extinction in the visible range. Here, we describe the feasibility of NAD(P)/NAD(P)H as redox agents in enzymatic plasmonic gold nanostar (AuNS) assays for galactose quantification using three model enzymes, GalDH, AR and GalOx, immobilized separately on polyvinylpyrrolidone-capped AuNS scaffolds. These highly specific, sensitive and selective bioassays induce the transformation of AuNS into quasi-spherical nanoparticles during the biorecognition of galactose in water and synthetic blood matrices. As a result, using our inexpensive and simple AuNS plasmon bioassays, the presence of galactose may be detected spectrophotometrically and by the naked eye.
- Open Access
- 1 December 2016
- Published by Elsevier in Atmospheric Environment
- Vol. 146, 113-131
The chemical composition and fluxes of atmospheric wet deposition at four sites in South Africa
- 1 December 2016
- Published by Elsevier in Atmospheric Environment
- Vol. 146, 113-131
Open AccessThe chemical composition and fluxes of atmospheric wet deposition at four sites in South Africa